<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Macrocytosis/Macrocytic anemia</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Macrocytosis/Macrocytic anemia</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Macrocytosis/Macrocytic anemia</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Wilma Barcellini, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert A Brodsky, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer S Tirnauer, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 08, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Macrocytosis is a descriptive term for red blood cell (RBC) size larger than the normal range. It may be caused by abnormalities of RBC production in the bone marrow, altered RBC membrane composition, or an increase in the percentage of reticulocytes, which are larger than mature RBCs. This topic discusses causes of macrocytosis and macrocytic anemia. Additional topics discuss the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Microcytosis/microcytic anemia – (See  <a class="medical medical_review" href="/d/html/4432.html" rel="external">"Microcytosis/Microcytic anemia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>General anemia evaluation</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Child – (See  <a class="medical medical_review" href="/d/html/5927.html" rel="external">"Approach to the child with anemia"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>Adult – (See  <a class="medical medical_review" href="/d/html/7133.html" rel="external">"Diagnostic approach to anemia in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Vitamin B12 and folate deficiency – (See  <a class="medical medical_review" href="/d/html/7155.html" rel="external">"Clinical manifestations and diagnosis of vitamin B12 and folate deficiency"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Myelodysplastic syndromes – (See  <a class="medical medical_review" href="/d/html/4492.html" rel="external">"Clinical manifestations, diagnosis, and classification of myelodysplastic syndromes (MDS)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hemolytic anemias – (See  <a class="medical medical_review" href="/d/html/5932.html" rel="external">"Overview of hemolytic anemias in children"</a> and  <a class="medical medical_review" href="/d/html/7076.html" rel="external">"Diagnosis of hemolytic anemia in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Alcohol-induced anemia – (See  <a class="medical medical_review" href="/d/html/7151.html" rel="external">"Hematologic complications of alcohol use"</a>.)</p><p></p><p class="headingAnchor" id="H3728312392"><span class="h1">DEFINITIONS AND CLASSIFICATION</span><span class="headingEndMark"> — </span>Macrocytosis is strictly a morphologic term and does not imply a specific pathophysiology. Macrocytosis can be documented using the mean corpuscular volume (MCV; also called mean cell volume) from an automated hematology instrument, measured in femtoliters (fL; 10<sup>-15</sup> liter) or by observing larger-than-normal RBCs on the peripheral blood smear.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Increased MCV</strong> – Macrocytosis is defined as an MCV above the upper limit of normal, which varies by age  (<a class="graphic graphic_table graphicRef52224" href="/d/graphic/52224.html" rel="external">table 1</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Preterm infants born at ≤25 weeks of gestation – 119 ± 7 fL</p><p class="bulletIndent2"><span class="glyph">•</span>Term newborns (cord blood) – 106 ± 4 fL</p><p class="bulletIndent2"><span class="glyph">•</span>Infants and young children – 90 fL</p><p class="bulletIndent2"><span class="glyph">•</span>Adults – 96 to 100 fL (the higher value may be more appropriate for older adults)</p><p></p><p class="bulletIndent1">The normal range is defined such that approximately 2.5 percent of the healthy population will have an MCV &gt;96 fL; &lt;0.5 percent will have a MCV &gt;100 fL. The MCV is reported routinely from automated hematology instruments along with other RBC indices  (<a class="graphic graphic_table graphicRef127504" href="/d/graphic/127504.html" rel="external">table 2</a>), and high values are flagged (often without adjustment for age).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>RDW </strong>– The RBC distribution width (RDW) is a measure of the variation in RBC sizes. A single uniform population of RBCs will have a normal RDW regardless of whether the absolute MCV is normal or abnormal. A population of RBCs with varied sizes or two populations of RBCs (eg, small RBCs plus reticulocytes) will have a large RDW (above approximately 14.5 percent when the coefficient of variation method is used). </p><p></p><p class="bulletIndent1">RDW is typically increased with concomitant disorders that cause macrocytosis and microcytosis (eg, vitamin B12 or folate deficiency plus iron deficiency) [<a href="#rid1">1</a>]. This finding suggests that it may be worthwhile to measure all of these nutrients when the RDW is increased.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Large RBCs on peripheral blood smear</strong> – The normal RBC diameter on the peripheral blood smear is 7 to 8 microns, approximately the size of the nucleus of a small lymphocyte  (<a class="graphic graphic_picture graphicRef74901" href="/d/graphic/74901.html" rel="external">picture 1</a>); RBCs that have a greater diameter are considered macrocytic. (See  <a class="medical medical_review" href="/d/html/4435.html" rel="external">"Evaluation of the peripheral blood smear"</a>.)</p><p></p><p class="bulletIndent1">Other findings on the peripheral blood smear that may be helpful in determining the cause of macrocytosis are discussed below. (See <a class="local">'Clues from the CBC and blood smear'</a> below.)</p><p></p><p>Megaloblastic anemia (or megaloblastic changes) describes a subset of macrocytic anemias in which the increased size of RBCs is caused by abnormal cell division in RBC precursors in the bone marrow (see <a class="local">'Pathophysiology'</a> below). The major associated finding on the blood smear is multilobed neutrophils. Typical bone marrow findings are described separately. (See  <a class="medical medical_review" href="/d/html/4434.html" rel="external">"Evaluation of bone marrow aspirate smears", section on 'Megaloblastic changes'</a>.)</p><p class="headingAnchor" id="H1195882705"><span class="h1">PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>Red blood cells (RBCs) leave the bone marrow as reticulocytes, which are macrocytic. All other macrocytic RBCs are formed as a consequence of inherited or acquired abnormalities in RBC maturation, nucleic acid metabolism, membrane composition, cell water content, or a combination of these factors  (<a class="graphic graphic_table graphicRef66772" href="/d/graphic/66772.html" rel="external">table 3</a>) [<a href="#rid2">2-4</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Increased reticulocytes</strong> – Reticulocytes are immature RBCs that have ejected their nuclei but retain some messenger RNA, making them appear slightly bluish/purplish (polychromatophilic) on a standard Wright-Giemsa stain. Reticulocytes in the bone marrow have a volume of 120 to 150 fL. After they enter the circulation they undergo loss of water and membrane and have a typical mean corpuscular volume (MCV) of approximately 103 to 126 fL, which is averaged into the MCV calculation by the automated instrument [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent1">In severe anemia the signal from erythropoietin to increase RBC production may cause developing RBCs to skip cell divisions and may cause reticulocytes to enter the circulation sooner than they otherwise would (eg, "stress" or "shunt" reticulocytes) and to circulate for longer periods of time, which may further increase the MCV  (<a class="graphic graphic_figure graphicRef61552" href="/d/graphic/61552.html" rel="external">figure 1</a>) [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent1">Reticulocytes can be recognized on the peripheral blood smear as larger RBCs that lack central pallor, are oval to irregular in outline, and have a blue tint (ie, polychromatophilia)  (<a class="graphic graphic_picture graphicRef67042" href="/d/graphic/67042.html" rel="external">picture 2</a>).</p><p></p><p class="bulletIndent1">Reticulocytosis is a normal physiologic response to anemia of any cause. It will occur unless the ability of the bone marrow to respond to anemia is blunted by other factors such as cytokines in anemia of chronic disease or vitamin or iron deficiency. Increased reticulocytes are a hallmark of hemolytic anemia and bone marrow recovery following a bone marrow insult, repletion of a deficient vitamin (B12 or folate) or iron, or hematopoietic cell transplant (HCT). Because reticulocytes are larger than mature RBCs, their increasing percentage of total RBCs will raise the MCV proportionately. (See  <a class="medical medical_review" href="/d/html/7076.html" rel="external">"Diagnosis of hemolytic anemia in adults", section on 'High reticulocyte count'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Abnormal RBC development/megaloblastic anemia</strong> – Developing RBC precursor cells in the bone marrow divide rapidly and become progressively smaller as they mature  (<a class="graphic graphic_figure graphicRef107367" href="/d/graphic/107367.html" rel="external">figure 2</a>). In conditions in which cell division is impaired, such as lack of a nutrient required for DNA synthesis, the synchrony between nuclear and cytoplasmic maturation may be lost, resulting in large, immature nuclei relative to the cytoplasm, along with other megaloblastic changes (eg, binucleate cells). The ultimate basis for production of the megaloblast is inadequate conversion of deoxyuridine to thymidylate (thymidine), which leads to slowing of DNA synthesis and delayed nuclear maturation. (See  <a class="medical medical_review" href="/d/html/7153.html" rel="external">"Causes and pathophysiology of vitamin B12 and folate deficiencies", section on 'Hematopoiesis'</a>.)</p><p></p><p class="bulletIndent1">Drugs and nutrient deficiencies that cause megaloblastic anemia will affect all developing blood cells, so similar abnormalities in white blood cell and platelet precursors can be seen in the bone marrow. The peripheral blood smear may show multilobed neutrophils, and the complete blood count may show mild pancytopenia. (See <a class="local">'Clues from the CBC and blood smear'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Abnormal RBC membrane</strong> – The RBC membrane is a complex lipid bilayer with integral membrane proteins attached to an underlying circumferential cytoskeleton that gives it mechanical stability and deformability. Certain inherited and acquired conditions can alter the membrane composition, and in some cases result in corresponding increases in cell volume. Examples include liver disease with increased membrane cholesterol content, and hereditary stomatocytosis with impaired volume regulation. (See <a class="local">'Causes of macrocytosis/macrocytic anemia'</a> below and  <a class="medical medical_review" href="/d/html/7151.html" rel="external">"Hematologic complications of alcohol use"</a> and  <a class="medical medical_review" href="/d/html/7068.html" rel="external">"Hereditary stomatocytosis (HSt) and hereditary xerocytosis (HX)"</a>.)</p><p></p><p>The presence of macrocytosis, along with the other RBC indices, the complete blood count, and the peripheral blood smear review, can be extremely helpful in evaluating the cause of anemia, or the early stage of a condition that is likely to cause anemia if untreated. (See <a class="local">'Evaluation'</a> below.)</p><p class="headingAnchor" id="H5831357"><span class="h1">CAUSES OF MACROCYTOSIS/MACROCYTIC ANEMIA</span></p><p class="headingAnchor" id="H3097267488"><span class="h2">Overview/common causes</span><span class="headingEndMark"> — </span>Causes of macrocytic anemia include the following  (<a class="graphic graphic_table graphicRef66772" href="/d/graphic/66772.html" rel="external">table 3</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Reticulocytosis</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hemolytic anemia</p><p class="bulletIndent2"><span class="glyph">•</span>Bone marrow recovery after chemotherapy or hematopoietic cell transplant (HCT)</p><p class="bulletIndent2"><span class="glyph">•</span>Increased erythropoiesis following administration of erythropoietin, repletion of iron, vitamin B12, or folate</p><p class="bulletIndent2"><span class="glyph">•</span>Recovery from bleeding episode</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Megaloblastic anemia </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Vitamin B12 or folate deficiency – (See <a class="local">'Megaloblastic anemia'</a> below.)</p><p class="bulletIndent2"><span class="glyph">•</span>Medications that interfere with DNA synthesis – (See <a class="local">'Drug-induced macrocytosis'</a> below.)</p><p class="bulletIndent2"><span class="glyph">•</span>Thiamine-responsive megaloblastic anemia – (See <a class="local">'Megaloblastic anemia'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Multifactorial</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Alcohol – (See <a class="local">'Alcohol/liver disease'</a> below.)</p><p class="bulletIndent2"><span class="glyph">•</span>Liver disease – (See <a class="local">'Alcohol/liver disease'</a> below.)</p><p class="bulletIndent2"><span class="glyph">•</span>HIV infection (and therapy) – (See  <a class="medical medical_review" href="/d/html/6679.html" rel="external">"HIV-associated cytopenias"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>Myelodysplastic syndrome – (See  <a class="medical medical_review" href="/d/html/4492.html" rel="external">"Clinical manifestations, diagnosis, and classification of myelodysplastic syndromes (MDS)"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>Hereditary stomatocytosis – (See  <a class="medical medical_review" href="/d/html/7068.html" rel="external">"Hereditary stomatocytosis (HSt) and hereditary xerocytosis (HX)"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>Hypothyroidism – (See  <a class="medical medical_review" href="/d/html/7846.html" rel="external">"Clinical manifestations of hypothyroidism", section on 'Anemia'</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>Pregnancy – (See  <a class="medical medical_review" href="/d/html/429.html" rel="external">"Maternal adaptations to pregnancy: Hematologic changes"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>Aplastic anemia – (See  <a class="medical medical_review" href="/d/html/7152.html" rel="external">"Aplastic anemia: Pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>Multiple myeloma – (See  <a class="medical medical_review" href="/d/html/6649.html" rel="external">"Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>Bariatric surgery (or, less commonly, other gastrointestinal surgery) – (See  <a class="medical medical_review" href="/d/html/587.html" rel="external">"Bariatric surgery: Postoperative nutritional management"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>Down syndrome – (See  <a class="medical medical_review" href="/d/html/2917.html" rel="external">"Down syndrome: Clinical features and diagnosis"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>Copper deficiency (although often causes normocytic anemia, and microcytic cells may be seen) – (See  <a class="medical medical_review" href="/d/html/7123.html" rel="external">"Sideroblastic anemias: Diagnosis and management", section on 'Copper deficiency'</a> and  <a class="medical medical_review" href="/d/html/2585.html" rel="external">"Overview of dietary trace elements", section on 'Copper'</a>.)</p><p></p><p>In the multifactorial conditions, the full mechanism may not be elucidated; there may be a combination of changes in the bone marrow, medication effects, and in some cases mild reticulocytosis. </p><p class="headingAnchor" id="H2062517871"><span class="h2">Reticulocytosis</span><span class="headingEndMark"> — </span>As noted above, an increase in the reticulocyte count and reticulocyte percentage is associated with a corresponding increase in mean corpuscular volume (MCV). (See <a class="local">'Pathophysiology'</a> above.) </p><p>Reticulocytosis can occur in any of the following settings:</p><p class="bulletIndent1"><span class="glyph">●</span>Any hemolytic anemia – (See  <a class="medical medical_review" href="/d/html/5932.html" rel="external">"Overview of hemolytic anemias in children"</a> and  <a class="medical medical_review" href="/d/html/7076.html" rel="external">"Diagnosis of hemolytic anemia in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Repletion of iron, vitamin B12, <a class="drug drug_general" data-topicid="8475" href="/d/drug information/8475.html" rel="external">folic acid</a>, or copper – (See  <a class="medical medical_review" href="/d/html/7148.html" rel="external">"Treatment of iron deficiency anemia in adults", section on 'Response to iron supplementation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Recovery from bleeding or transient bone marrow aplasia (eg, following parvovirus infection) – (See  <a class="medical medical_review" href="/d/html/7133.html" rel="external">"Diagnostic approach to anemia in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Any other condition associated with increased erythropoietin, such as congenital heart disease, erythropoietin-secreting tumors, or "blood doping" – (See  <a class="medical medical_review" href="/d/html/7161.html" rel="external">"Regulation of erythropoiesis"</a>.)</p><p></p><p class="headingAnchor" id="H322328536"><span class="h2">Megaloblastic anemia</span><span class="headingEndMark"> — </span>As noted above, megaloblastic anemia is a form of macrocytic anemia in which nucleic acid metabolism is impaired, leading to reduced efficiency of cell division and nuclear-cytoplasmic dyssynchrony. (See <a class="local">'Pathophysiology'</a> above.)</p><p>Causes of megaloblastic anemia include deficiency of vitamin B12, folate, or copper, as well as a number of medications that interfere with DNA synthesis.</p><p class="bulletIndent1"><span class="glyph">●</span>Vitamin B12 deficiency has numerous causes related to its complex absorption  (<a class="graphic graphic_table graphicRef77437" href="/d/graphic/77437.html" rel="external">table 4</a>). (See  <a class="medical medical_review" href="/d/html/7154.html" rel="external">"Treatment of vitamin B12 and folate deficiencies"</a> and  <a class="medical medical_review" href="/d/html/7153.html" rel="external">"Causes and pathophysiology of vitamin B12 and folate deficiencies"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Folate deficiency has become increasingly rare in countries in which certain foods are routinely supplemented with folate. However, it may occur in countries where routine <a class="drug drug_general" data-topicid="8475" href="/d/drug information/8475.html" rel="external">folic acid</a> supplementation of foods does not occur, or in individuals with severe malnutrition or certain dietary practices  (<a class="graphic graphic_table graphicRef55010" href="/d/graphic/55010.html" rel="external">table 5</a>). Folate deficiency was also common in individuals with increased folate requirement such as those with chronic eczema (21 of 28 individuals [75 percent] in one series) in the era before routine supplementation was initiated [<a href="#rid6">6</a>]. (See <a class="local">'Clues from the history and examination'</a> below.)</p><p></p><p class="bulletIndent1">Relative folate deficiency is a common finding in all hemolytic conditions with increased bone marrow compensation and reticulocytosis. (See  <a class="medical medical_review" href="/d/html/7078.html" rel="external">"Warm autoimmune hemolytic anemia (AIHA) in adults", section on 'Folic acid'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Thiamine-responsive megaloblastic anemia syndrome (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F249270&amp;token=87jLzclRwWxNoI%2BQq5Gg7yXKyyQtxHd8DAB58Q2W6fjVHEfldggyciYsBaP0oTO%2B&amp;TOPIC_ID=7166" target="_blank">TRMA</a>) is an exquisitely rare autosomal recessive disorder characterized by anemia, diabetes, and early-onset sensorineural hearing loss [<a href="#rid7">7-9</a>]. Ocular and cardiac manifestations have also been reported [<a href="#rid10">10,11</a>]. Various mutations in a gene encoding a thiamine transporter (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fomim.org%2Fentry%2F603941&amp;token=87jLzclRwWxNoI%2BQq5Gg75Bi6W%2FdZupD2Or31SqE7Wg8B9yC%2BRSnuhEaaBNWlNxE&amp;TOPIC_ID=7166" target="_blank">SLC19A2</a>) have been identified. Disease onset is in infancy through adolescence. The anemia improves with administration of high doses of thiamine (vitamin B1). (See  <a class="medical medical_review" href="/d/html/5367.html" rel="external">"Overview of water-soluble vitamins", section on 'Vitamin B1 (thiamine)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>As a result of reductions in vitamin B12 and folate deficiency, drug-induced megaloblastic anemia has accounted for a larger proportion of megaloblastic anemia in some settings [<a href="#rid12">12</a>]. (See <a class="local">'Drug-induced macrocytosis'</a> below.)</p><p></p><p class="headingAnchor" id="H345454997"><span class="h2">Myelodysplastic syndrome</span><span class="headingEndMark"> — </span>Myelodysplastic syndrome (MDS) is characterized by anemia in almost all cases, which may be macrocytic or normocytic. The reticulocyte response is generally inappropriately low. The RDW is often increased. Details are presented separately. (See  <a class="medical medical_review" href="/d/html/4492.html" rel="external">"Clinical manifestations, diagnosis, and classification of myelodysplastic syndromes (MDS)"</a>.)</p><p class="headingAnchor" id="H208692063"><span class="h2">Drug-induced macrocytosis</span><span class="headingEndMark"> — </span>Medications potentially implicated in causing macrocytic anemia include the following [<a href="#rid12">12-23</a>]; many of these cause megaloblastic anemia, although some cause hemolytic anemia, and the resulting reticulocytosis increases the MCV:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8439" href="/d/drug information/8439.html" rel="external">Allopurinol</a> (megaloblastic changes)</p><p class="bulletIndent1"><span class="glyph">●</span>Aminosalicylic acid (reduces folate absorption)</p><p class="bulletIndent1"><span class="glyph">●</span>Antacids (reduce vitamin B12 absorption) </p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8737" href="/d/drug information/8737.html" rel="external">Ampicillin</a> and other penicillins (reduces folate absorption)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">Azathioprine</a> (megaloblastic changes)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">Capecitabine</a> (megaloblastic changes)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9241" href="/d/drug information/9241.html" rel="external">Chloramphenicol</a> (reduces folate absorption)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9272" href="/d/drug information/9272.html" rel="external">Cladribine</a> (megaloblastic changes)</p><p class="bulletIndent1"><span class="glyph">●</span>Cytosine arabinoside (ara-C) (megaloblastic changes)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9324" href="/d/drug information/9324.html" rel="external">Dapsone</a> (hemolysis in individuals with G6PD deficiency)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9418" href="/d/drug information/9418.html" rel="external">Erythromycin</a> (reduces folate absorption)</p><p class="bulletIndent1"><span class="glyph">●</span>Estrogens or hormonal contraceptives (reduces folate absorption)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8452" href="/d/drug information/8452.html" rel="external">Fludarabine</a> (megaloblastic changes)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">Fluorouracil</a> (megaloblastic changes)</p><p class="bulletIndent1"><span class="glyph">●</span>Gadolinium (megaloblastic changes)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">Gemcitabine</a> (megaloblastic changes)</p><p class="bulletIndent1"><span class="glyph">●</span>Histamine H2 receptor antagonists (eg, <a class="drug drug_general" data-topicid="9265" href="/d/drug information/9265.html" rel="external">cimetidine</a>, <a class="drug drug_general" data-topicid="8436" href="/d/drug information/8436.html" rel="external">famotidine</a>, <a class="drug drug_general" data-topicid="9708" href="/d/drug information/9708.html" rel="external">nizatidine</a>; reduce vitamin B12 absorption)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">Hydroxyurea</a> (megaloblastic changes)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8961" href="/d/drug information/8961.html" rel="external">Imatinib</a> (unknown; possibly inhibition of c-kit)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9544" href="/d/drug information/9544.html" rel="external">Lamivudine</a> (megaloblastic changes)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10097" href="/d/drug information/10097.html" rel="external">Leflunomide</a> (megaloblastic changes)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9612" href="/d/drug information/9612.html" rel="external">Mercaptopurine</a> (megaloblastic changes)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">Metformin</a> (interferes with folate metabolism)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">Methotrexate</a> (megaloblastic changes)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9636" href="/d/drug information/9636.html" rel="external">Methylene blue</a> (hemolysis in individuals with G6PD deficiency)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">Mycophenolate</a> mofetil (megaloblastic changes)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9704" href="/d/drug information/9704.html" rel="external">Nitrofurantoin</a> (reduces folate absorption, hemolysis in individuals with G6PD deficiency)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10086" href="/d/drug information/10086.html" rel="external">Nitrous oxide</a> (megaloblastic changes)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="16076" href="/d/drug information/16076.html" rel="external">Pegloticase</a> (hemolysis in individuals with G6PD deficiency)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9756" href="/d/drug information/9756.html" rel="external">Pentostatin</a> (megaloblastic changes)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">Phenytoin</a> (interferes with folate metabolism)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9810" href="/d/drug information/9810.html" rel="external">Primaquine</a> (hemolysis in individuals with G6PD deficiency)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9811" href="/d/drug information/9811.html" rel="external">Primidone</a> (unknown)</p><p class="bulletIndent1"><span class="glyph">●</span>Proton pump inhibitors (eg, <a class="drug drug_general" data-topicid="9718" href="/d/drug information/9718.html" rel="external">omeprazole</a>, <a class="drug drug_general" data-topicid="9546" href="/d/drug information/9546.html" rel="external">lansoprazole</a>; reduce B12 absorption)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9946" href="/d/drug information/9946.html" rel="external">Stavudine</a> (megaloblastic changes)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10189" href="/d/drug information/10189.html" rel="external">Rasburicase</a> (hemolysis in individuals with G6PD deficiency)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">Sunitinib</a> (unknown; possibly inhibition of c-kit)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="86616" href="/d/drug information/86616.html" rel="external">Teriflunomide</a> (megaloblastic changes)</p><p class="bulletIndent1"><span class="glyph">●</span>Tetracyclines (reduces folate absorption)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9989" href="/d/drug information/9989.html" rel="external">Thioguanine</a> (megaloblastic changes)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10016" href="/d/drug information/10016.html" rel="external">Triamterene</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10024" href="/d/drug information/10024.html" rel="external">Trimethoprim</a> (megaloblastic changes)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10035" href="/d/drug information/10035.html" rel="external">Valproic acid</a></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10053" href="/d/drug information/10053.html" rel="external">Zidovudine</a> (megaloblastic changes)</p><p></p><p>Of these, we most commonly see macrocytosis from <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a> for sickle cell disease, chemotherapeutic agents, and antiretroviral therapy (ART) in patients with HIV infection. (See  <a class="medical medical_review" href="/d/html/13978.html" rel="external">"Overview of antiretroviral agents used to treat HIV", section on 'Non-nucleoside reverse transcriptase inhibitors (NNRTIs)'</a>.)</p><p>A more extensive discussion of drugs that cause hemolytic anemia is presented separately. (See  <a class="medical medical_review" href="/d/html/7104.html" rel="external">"Drug-induced hemolytic anemia"</a>.)</p><p class="headingAnchor" id="H2201811559"><span class="h2">Alcohol/liver disease</span><span class="headingEndMark"> — </span>Alcohol is a common cause of macrocytosis and macrocytic anemia. Regular ingestion of 80 grams of alcohol each day (eg, one bottle of wine) is sufficient to cause this effect [<a href="#rid2">2</a>]. Even before anemia appears, chronic alcohol users have a mild macrocytosis (typical mean corpuscular volume [MCV] between 100 and 110 fL) [<a href="#rid24">24-26</a>]. (See <a class="local">'Clues from the history and examination'</a> below.)</p><p>Alcohol-induced macrocytosis occurs even in patients who are folate and cobalamin replete and do not have liver disease. Abstinence from alcohol results in resolution of the macrocytosis within two to four months. Return of the MCV to normal also confirms the diagnosis. (See  <a class="medical medical_review" href="/d/html/7151.html" rel="external">"Hematologic complications of alcohol use", section on 'Anemia'</a>.)</p><p>In a series of 168 chronic alcohol users from the 1970s, half had macrocytosis with a mean MCV of 98 fL; in those with concomitant liver disease, 64 percent had macrocytosis with a mean MCV of 100 fL [<a href="#rid27">27</a>]. In a 1990 series of 73 individuals with macrocytosis identified from a primary care practice, macrocytosis was ascribed to alcohol in 47 (64 percent) [<a href="#rid28">28</a>]. In another primary care series of 300 individuals with macrocytosis, approximately a third of the women and four-fifths of the men were alcohol abusers [<a href="#rid29">29</a>].</p><p>The mechanism of alcohol-induced macrocytosis is unknown. Acetaldehyde, a metabolic breakdown product of alcohol, is capable of inducing membrane changes in red blood cell (RBC) precursors and circulating RBCs of individuals with alcohol-associated macrocytosis, through the in vivo production of acetaldehyde adducts [<a href="#rid30">30</a>]. Acetaldehyde also interferes with cell division and may increase cell volume by this mechanism [<a href="#rid31">31</a>]. In addition, one study has shown a significant correlation between the MCV in heavy drinkers (&gt;300 grams of alcohol per week) and the genotype of the aldehyde dehydrogenase responsible for ethanol metabolism [<a href="#rid32">32</a>]. (See  <a class="medical medical_review" href="/d/html/3613.html" rel="external">"Pathogenesis of alcohol-associated liver disease"</a>.)</p><p>Other forms of liver disease not related to alcohol may cause macrocytosis by effects on the lipid composition of the RBC membrane [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/d/html/1253.html" rel="external">"Cirrhosis in adults: Etiologies, clinical manifestations, and diagnosis", section on 'Hematologic abnormalities'</a>.)</p><p class="headingAnchor" id="H4089787659"><span class="h2">Vitamins and trace minerals</span><span class="headingEndMark"> — </span>Gastric bypass surgery is associated with micronutrient malabsorption related to the physical bypass or removal of absorptive cells as well as reduced dietary intake and other mechanisms; the risk of nutrient deficiencies is greater with bypass procedures than restrictive procedures such as gastric banding. Patients may develop combined deficiencies of vitamin B12, folate, and iron if they do not receive supplementation. Copper deficiency can also occur. (See  <a class="medical medical_review" href="/d/html/587.html" rel="external">"Bariatric surgery: Postoperative nutritional management"</a>.)</p><p>These vitamin and mineral deficiencies may also arise in other settings such as <a class="drug drug_general" data-topicid="10307" href="/d/drug information/10307.html" rel="external">parenteral nutrition</a> without adequate supplementation or the use of infant formulas that lack these constituents [<a href="#rid33">33</a>]. Other malabsorption syndromes or the use of chelating agents may also lead to single or multiple deficiencies. (See  <a class="medical medical_review" href="/d/html/5886.html" rel="external">"Chronic complications of short bowel syndrome in children", section on 'Nutritional complications'</a> and  <a class="medical medical_review" href="/d/html/4780.html" rel="external">"Approach to the adult patient with suspected malabsorption"</a> and  <a class="medical medical_review" href="/d/html/4782.html" rel="external">"Overview of the treatment of malabsorption in adults"</a> and  <a class="medical medical_review" href="/d/html/15634.html" rel="external">"Parenteral nutrition in infants and children"</a>.)</p><p>Excessive ingestion of zinc may lead to copper deficiency, including the common use of zinc as a denture adhesive. (See  <a class="medical medical_review" href="/d/html/16517.html" rel="external">"Copper deficiency myeloneuropathy", section on 'Causes of acquired copper deficiency'</a>.)</p><p>As noted above, <a class="drug drug_general" data-topicid="10086" href="/d/drug information/10086.html" rel="external">nitrous oxide</a> can cause vitamin B12 deficiency. (See <a class="local">'Drug-induced macrocytosis'</a> above.)</p><p>In addition to acquired micronutrient and trace mineral deficiencies, rare genetic conditions affecting vitamin and mineral metabolism may lead to macrocytic anemia. (See  <a class="medical medical_review" href="/d/html/7154.html" rel="external">"Treatment of vitamin B12 and folate deficiencies"</a> and  <a class="medical medical_review" href="/d/html/16517.html" rel="external">"Copper deficiency myeloneuropathy"</a>.)</p><p class="headingAnchor" id="H631838094"><span class="h2">Hypothyroidism</span><span class="headingEndMark"> — </span>Macrocytosis can occur in the setting of hypothyroidism. The mechanism is unclear and may be multifactorial in some patients.</p><p>In a series of 202 patients with hypothyroidism from 1976, anemia was present in 53 (26 percent) [<a href="#rid1">1</a>]. A subset of 53 individuals who were analyzed in more detail had macrocytosis despite normal levels of vitamin B12, folate, and iron. Of these, 13 (25 percent) had anemia that resolved upon treatment with thyroxine. Patients with autoimmune hypothyroidism may have concomitant vitamin B12 deficiency caused by autoantibodies to gastric parietal cells. In the series of 202 patients, 10 of 118 (8.5 percent) had concomitant pernicious anemia.</p><p>The typical MCV in hypothyroidism is mildly increased (in the range of 90 to 100 fL). </p><p class="headingAnchor" id="H4262228745"><span class="h2">Macrocytosis with mild or no anemia</span><span class="headingEndMark"> — </span>In addition to mild forms of the conditions discussed above, macrocytosis may be seen in newborns (in which case the upper limit of normal for the MCV is age-adjusted), during pregnancy, and in some older adults.</p><p>A full evaluation including history, physical examination, and extensive laboratory testing as discussed below often reveals no abnormalities, and the peripheral blood smear shows only macrocytic RBCs (see <a class="local">'Evaluation'</a> below). The underlying concern is that this may be a harbinger of myelodysplastic syndrome (MDS). Some consultants proceed to a bone marrow examination with cytogenetics, myelodysplasia fluorescence in situ hybridization (FISH) panel, and comprehensive somatic mutation panel. There are no data showing that this approach results in a clarifying diagnosis. Others prefer to watch and follow. Studies to clarify the benefits of each approach are needed. (See <a class="local">'Age of the patient'</a> below.)</p><p class="headingAnchor" id="H1723871908"><span class="h1">EVALUATION</span></p><p class="headingAnchor" id="H2014801926"><span class="h2">Initial considerations</span><span class="headingEndMark"> — </span>Before embarking on an extensive evaluation, it is appropriate to confirm that macrocytosis is real and not artifactual. Causes of spurious macrocytosis include clumping of red blood cells (RBCs) (eg, by cold agglutinins), osmotic swelling of RBCs in the setting of severe hyperglycemia (eg, blood glucose levels above 625 mg/dL [35 mmol/L]) or prolonged storage, or high concentrations of certain forms of EDTA as an anticoagulant in the blood collection tube (although EDTA can also cause microcytosis) [<a href="#rid34">34-39</a>]. (See  <a class="medical medical_review" href="/d/html/4430.html" rel="external">"Automated complete blood count (CBC)", section on 'Sample collection and processing'</a>.)</p><p>These possibilities can generally be eliminated by repeating the complete blood count and reviewing the peripheral blood smear. If cold agglutinins are suspected, the sample can be warmed prior to analysis.</p><p>While the mean value for the MCV in adults is 88 fL, a number of studies of non-anemic ambulatory adults over age 65 have reported mean values ranging from 91 to 93 fL, with up to 10 percent having a MCV &gt;96 fL, and 2 to 6 percent having a MCV &gt;100 fL [<a href="#rid40">40-43</a>]. Thus, we generally do not initiate an intensive evaluation of older adults for an MCV in the range between 96 and 100 fL, unless the patient is anemic or the MCV value represents a meaningful change from the individual’s baseline. (See <a class="local">'Macrocytosis with mild or no anemia'</a> above.)</p><p class="headingAnchor" id="H3741576282"><span class="h2">Clues from the history and examination</span><span class="headingEndMark"> — </span>Patient age, medical history, alcohol use, and medications are especially important in the evaluation of macrocytosis  (<a class="graphic graphic_algorithm graphicRef108047" href="/d/graphic/108047.html" rel="external">algorithm 1</a>).</p><p class="headingAnchor" id="H3580777794"><span class="h3">Age of the patient</span><span class="headingEndMark"> — </span>As noted above, normal values for the MCV are higher in neonates (especially those born preterm) and infants; age-appropriate values should be consulted  (<a class="graphic graphic_table graphicRef52224" href="/d/graphic/52224.html" rel="external">table 1</a>) [<a href="#rid44">44-46</a>]. (See  <a class="medical medical_review" href="/d/html/5927.html" rel="external">"Approach to the child with anemia", section on 'Red blood cell indices'</a>.)</p><p>In children, common causes of macrocytosis/macrocytic anemia include drugs and conditions present from birth. A 1992 retrospective series of 146 children with macrocytosis identified the following as common causes [<a href="#rid46">46</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Medications (eg, anticonvulsants, <a class="drug drug_general" data-topicid="10053" href="/d/drug information/10053.html" rel="external">zidovudine</a>, immunosuppressive agents) – 51 (35 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Congenital heart disease – 20 (14 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Down syndrome – 12 (8 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Reticulocytosis – 11 (8 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Bone marrow failure/dysplasia – 6 (4 percent)</p><p></p><p>Rare causes of macrocytosis in children include inherited defects in vitamin B12 or thiamine metabolism that cause megaloblastic anemia. (See <a class="local">'Megaloblastic anemia'</a> above.)</p><p>In adults, common causes of macrocytosis/macrocytic anemia include alcohol use or abuse, liver disease, thyroid disease, and megaloblastic anemias [<a href="#rid22">22,47</a>]. Hemolytic anemias with reticulocytosis and bone marrow failure states including myelodysplastic syndromes (MDS), aplastic anemia, and paroxysmal nocturnal hemoglobinuria (PNH) are also seen. (See  <a class="medical medical_review" href="/d/html/4492.html" rel="external">"Clinical manifestations, diagnosis, and classification of myelodysplastic syndromes (MDS)"</a>.)</p><p>Macrocytosis is a common presenting feature of MDS, especially in older adults [<a href="#rid48">48</a>]. In one series of bone marrow examinations that included mostly older adults, a score including unexplained macrocytosis, abnormal RBC distribution width (RDW), and elevated lactate dehydrogenase (LDH) identified 114 of 313 (36 percent) as having MDS [<a href="#rid40">40</a>]. Many did not have an ultimate diagnosis even after bone marrow evaluation. As noted above, there are not good data suggesting that an extensive evaluation for MDS improves outcomes in this setting. (See <a class="local">'Macrocytosis with mild or no anemia'</a> above.)</p><p class="headingAnchor" id="H436950189"><span class="h3">Medications</span><span class="headingEndMark"> — </span>Typically, medications that cause megaloblastic anemia will be obvious from the medical history. These include <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a>, certain chemotherapy agents, and combination antiretroviral therapy (ART) for HIV infection. (See <a class="local">'Drug-induced macrocytosis'</a> above.)</p><p>Other medications that may be less obvious causes of macrocytosis include those that cause hemolysis in individuals with glucose-6-phosphate dehydrogenase deficiency (G6PD), over-the-counter antacids or medications to reduce gastric acid production, which may reduce vitamin B12 absorption, and certain antibiotics. (See <a class="local">'Drug-induced macrocytosis'</a> above.)</p><p>The use of <a class="drug drug_general" data-topicid="10086" href="/d/drug information/10086.html" rel="external">nitrous oxide</a> anesthesia (or as a recreational drug) has also been reported to cause macrocytic anemia, possibly by inducing transient vitamin B12 deficiency.</p><p class="headingAnchor" id="H3721306042"><span class="h3">Alcohol</span><span class="headingEndMark"> — </span>Alcohol use is considered to be under-reported and should be specifically queried in the context of macrocytosis. (See <a class="local">'Alcohol/liver disease'</a> above.)</p><p class="headingAnchor" id="H2531136710"><span class="h3">Diet</span><span class="headingEndMark"> — </span>The dietary history may be helpful in identifying the use of an infant formula or formula substitute that may lack sufficient nutrients, strict vegetarians who do not take supplemental vitamin B12, poor nutritional intake, or other unusual dietary practices. Excessive intake of zinc has been reported to cause copper deficiency. (See <a class="local">'Vitamins and trace minerals'</a> above.)</p><p class="headingAnchor" id="H906036199"><span class="h2">Clues from the CBC and blood smear</span><span class="headingEndMark"> — </span>The severity of macrocytosis, presence of other cytopenias, and specific RBC morphologies on the peripheral blood smear may be useful in narrowing the possible causes of macrocytosis and in guiding the evaluation  (<a class="graphic graphic_algorithm graphicRef108047" href="/d/graphic/108047.html" rel="external">algorithm 1</a>).</p><p class="bulletIndent1"><span class="glyph">●</span>Severe macrocytosis (MCV above 110 to 115 fL) is associated almost exclusively with megaloblastic anemias. This was illustrated in a series of 109 individuals with MCV &gt;130 fL from 2014 [<a href="#rid49">49</a>]. Over 90 percent of the cases were due to one of the following: ART treatment of HIV infection, use of <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a>, or a deficiency of vitamin B12 or folate. As noted above, an extremely high MCV may also be a clue to an artifactually high MCV caused by RBC agglutination. (See <a class="local">'Evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Anemia plus one or more additional cytopenias (leukopenia and/or thrombocytopenia) is suggestive of a primary bone marrow problem (eg, megaloblastic anemia, myelodysplasia). If a drug-induced cause or a vitamin B12, folate, or copper deficiency is not diagnosed from the history or initial testing, bone marrow evaluation usually is indicated. (See <a class="local">'Bone marrow/hematologist referral'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The following findings on the blood smear and their associated conditions may be helpful, although none are pathognomonic for a specific condition:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Target cells  (<a class="graphic graphic_picture graphicRef80318" href="/d/graphic/80318.html" rel="external">picture 3</a>) are suggestive of liver disease.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Macro-ovalocytes  (<a class="graphic graphic_picture graphicRef74901" href="/d/graphic/74901.html" rel="external">picture 1</a>) are suggestive of a megaloblastic process such as vitamin B12, folate, or copper deficiency; or drug-induced megaloblastic anemia; or membrane disorders such as hereditary stomatocytosis (HSt) or hereditary xerocytosis (HX). (See  <a class="medical medical_review" href="/d/html/7068.html" rel="external">"Hereditary stomatocytosis (HSt) and hereditary xerocytosis (HX)"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Spherocytes such as in hereditary spherocytosis or autoimmune hemolytic anemia. (See  <a class="medical medical_review" href="/d/html/7079.html" rel="external">"Hereditary spherocytosis"</a> and  <a class="medical medical_review" href="/d/html/7078.html" rel="external">"Warm autoimmune hemolytic anemia (AIHA) in adults"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>RBC agglutination as in cold agglutinin disease (CAD). (See  <a class="medical medical_review" href="/d/html/7084.html" rel="external">"Cold agglutinin disease"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Neutrophils with more than five distinct lobes  (<a class="graphic graphic_picture graphicRef58820" href="/d/graphic/58820.html" rel="external">picture 4</a>) (referred to as multilobed or hypersegmented neutrophils) are suggestive of a megaloblastic process.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Neutrophils with fewer than three distinct lobes (referred to as hypolobulated neutrophils or pseudo-Pelger-Huet cells) and/or reduced number of cytoplasmic granules (hypogranular neutrophils) are associated with myelodysplasia  (<a class="graphic graphic_picture graphicRef71990" href="/d/graphic/71990.html" rel="external">picture 5</a>).</p><p></p><p class="headingAnchor" id="H1698583494"><span class="h2">Initial testing</span><span class="headingEndMark"> — </span>In addition to a review of the complete blood count (CBC) including RBC indices and other cell lines, individuals for whom the history does not point to a clear diagnosis should have one or more of the following tests:</p><p class="bulletIndent1"><span class="glyph">●</span>Reticulocyte count</p><p class="bulletIndent1"><span class="glyph">●</span>Serum vitamin B12 and folate level</p><p class="bulletIndent1"><span class="glyph">●</span>Thyroid-stimulating hormone (TSH)</p><p class="bulletIndent1"><span class="glyph">●</span>Liver function tests</p><p class="bulletIndent1"><span class="glyph">●</span>Copper level, especially in individuals who have undergone gastric bypass surgery</p><p></p><p>Whether these are done simultaneously or sequentially depends on other clinical features, the degree of suspicion of one or more of the likely causes of macrocytosis, and the acuity and severity of anemia.</p><p>In a patient without anemia, reticulocytes make up 1 to 2 percent of RBCs. Hemolytic anemia typically raises the reticulocyte percentage above 4 to 5 percent as long as bone marrow function is adequate and vitamin B12, folate, and iron are available. It is also appropriate to perform other testing such as haptoglobin and lactate dehydrogenase (LDH) if the reticulocyte count is not dramatically increased but hemolysis is suspected. Additional information regarding interpretation of the absolute reticulocyte count and evaluation for the cause of hemolysis is presented separately. (See  <a class="medical medical_review" href="/d/html/7076.html" rel="external">"Diagnosis of hemolytic anemia in adults"</a>.)</p><p>If the vitamin B12 or folate level is in the borderline range, it may be necessary to perform additional testing for methylmalonic acid and homocysteine levels.</p><p>A small percentage of individuals with multiple myeloma have macrocytosis, either due to concomitant vitamin B12 deficiency or from an unknown mechanism. If the patient has any findings suggestive of multiple myeloma such as back pain, hypercalcemia, or renal insufficiency, serum protein electrophoresis (SPEP) should be performed. (See  <a class="medical medical_review" href="/d/html/6649.html" rel="external">"Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis", section on 'Anemia'</a>.)</p><p class="headingAnchor" id="H3006765451"><span class="h2">Response to therapy as confirmation</span><span class="headingEndMark"> — </span>Importantly, macrocytosis or macrocytic anemia should resolve with appropriate treatment based on a documented diagnosis. If macrocytosis or anemia persists despite correction of an underlying abnormality, investigation for additional causes of anemia is appropriate.</p><p class="headingAnchor" id="H2958586119"><span class="h2">Bone marrow/hematologist referral</span><span class="headingEndMark"> — </span>In cases where the cause of macrocytosis is not obvious from preliminary laboratory testing, hematologist referral is appropriate to evaluate the possibility of less-common causes of chronic hemolytic anemia and underlying bone marrow disorders such as myelodysplasia. Bone marrow evaluation for signs of dysplasia, hematologic malignancy, or abnormality of RBC maturation is appropriate if there is pancytopenia or if the initial testing listed above does not provide a diagnosis. (See <a class="local">'Initial testing'</a> above.)</p><p>Bone marrow testing should include standard morphologic analysis as well as iron staining, as well as cytogenetic analysis in cases of possible myelodysplasia or hematologic malignancy. The usefulness of genetic testing with a myeloid somatic mutation panel has not been studied. (See  <a class="medical medical_review" href="/d/html/4434.html" rel="external">"Evaluation of bone marrow aspirate smears"</a> and  <a class="medical medical_review" href="/d/html/4436.html" rel="external">"Bone marrow aspiration and biopsy: Indications and technique", section on 'Preparation of samples'</a>.)</p><p class="headingAnchor" id="H480206883"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/111043.html" rel="external">"Society guideline links: Anemia in adults"</a>.)</p><p class="headingAnchor" id="H16"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definitions</strong> –<strong> </strong>Macrocytosis is defined as a red blood cell (RBC) mean corpuscular volume (MCV) above the upper limit of normal, which is typically &gt;96 to 100 femtoliters (fL) in adults. Neonates, infants, and young children have a higher upper limit of normal. Macrocytic anemia can be further classified according to the presence of reticulocytes and megaloblastic changes on the peripheral blood smear. (See <a class="local">'Definitions and classification'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanisms </strong>– RBCs leave the bone marrow as reticulocytes, which are macrocytic. All other macrocytic RBCs are formed as a consequence of inherited or acquired abnormalities in RBC maturation, nucleic acid metabolism, membrane composition, cell water content, or a combination of these factors. (See <a class="local">'Pathophysiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Causes </strong>– Causes of macrocytic anemia include reticulocytosis in the setting of hemolytic anemia, bone marrow recovery, or erythropoietin; megaloblastic anemia from vitamin deficiency, drugs that interfere with nucleic acid metabolism or cell division, or rare inherited conditions; and a number of multifactorial processes such as alcohol, liver disease, hypothyroidism, myelodysplasia, and others listed above. (See <a class="local">'Causes of macrocytosis/macrocytic anemia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation </strong>– Patient age, medical history, alcohol use, and medications are especially important in the evaluation of macrocytosis  (<a class="graphic graphic_algorithm graphicRef108047" href="/d/graphic/108047.html" rel="external">algorithm 1</a>). Age-appropriate normal ranges for the MCV should be consulted for neonates and infants. Medications should be checked, alcohol use discussed, and dietary practices reviewed. (See <a class="local">'Clues from the history and examination'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CBC and blood smear review </strong>– The severity of macrocytosis, presence of other cytopenias on the complete blood count (CBC), and specific RBC morphologies on the peripheral blood smear may be useful in narrowing the possible causes of macrocytosis and in guiding the evaluation  (<a class="graphic graphic_algorithm graphicRef108047" href="/d/graphic/108047.html" rel="external">algorithm 1</a>). Severe macrocytosis (MCV above 110 to 115 fL) is associated almost exclusively with megaloblastic anemias. Anemia plus one or more additional cytopenias (leukopenia and/or thrombocytopenia) is suggestive of a primary bone marrow problem (eg, megaloblastic anemia, myelodysplasia). Helpful findings on the blood smear are discussed above. (See <a class="local">'Clues from the CBC and blood smear'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Additional laboratory testing</strong> – Individuals for whom the history does not point to a clear diagnosis should have a reticulocyte count; serum vitamin B12 (cobalamin), folate, and copper levels; thyroid-stimulating hormone (TSH); and liver function tests. Additional testing such as serum protein electrophoresis (SPEP) may occasionally be appropriate if the other tests are normal or there are clinical features of multiple myeloma, as myeloma is occasionally associated with macrocytosis. (See <a class="local">'Initial testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hematologist input and bone marrow</strong> – If the preliminary evaluation is negative or there is severe pancytopenia, referral to a hematologist and bone marrow evaluation are appropriate. In addition to standard morphology and iron staining, cytogenetic analysis and a myeloid somatic mutation panel may define myelodysplastic syndromes (MDS). (See <a class="local">'Bone marrow/hematologist referral'</a> above and  <a class="medical medical_review" href="/d/html/4492.html" rel="external">"Clinical manifestations, diagnosis, and classification of myelodysplastic syndromes (MDS)"</a>.)</p><p></p><p class="headingAnchor" id="H2322452418"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>UpToDate gratefully acknowledges Stanley L Schrier, MD (deceased), who contributed as Section Editor on earlier versions of this topic review and was a founding Editor-in-Chief for UpToDate in Hematology.</p><p>The UpToDate editorial staff also acknowledges the extensive contributions of William C Mentzer, MD, to earlier versions of this and many other topic reviews.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Horton L, Coburn RJ, England JM, Himsworth RL. The haematology of hypothyroidism. Q J Med 1976; 45:101.</a></li><li><a class="nounderline abstract_t">Hoffbrand V, Provan D. ABC of clinical haematology. Macrocytic anaemias. BMJ 1997; 314:430.</a></li><li><a class="nounderline abstract_t">Colon-Otero G, Menke D, Hook CC. A practical approach to the differential diagnosis and evaluation of the adult patient with macrocytic anemia. Med Clin North Am 1992; 76:581.</a></li><li><a class="nounderline abstract_t">d'Onofrio G, Chirillo R, Zini G, et al. Simultaneous measurement of reticulocyte and red blood cell indices in healthy subjects and patients with microcytic and macrocytic anemia. Blood 1995; 85:818.</a></li><li><a class="nounderline abstract_t">Houwen B. Reticulocyte maturation. Blood Cells 1992; 18:167.</a></li><li><a class="nounderline abstract_t">Shuster S, Marks J, Chanarin I. Folic acid deficiency in patients with skin disease. Br J Dermatol 1967; 79:398.</a></li><li><a class="nounderline abstract_t">Borgna-Pignatti C, Azzalli M, Pedretti S. Thiamine-responsive megaloblastic anemia syndrome: long term follow-up. J Pediatr 2009; 155:295.</a></li><li><a class="nounderline abstract_t">Viana MB, Carvalho RI. Thiamine-responsive megaloblastic anemia, sensorineural deafness, and diabetes mellitus: A new syndrome? J Pediatr 1978; 93:235.</a></li><li><a class="nounderline abstract_t">Porter FS, Rogers LE, Sidbury JB Jr. Thiamine-responsive megaloblastic anemia. J Pediatr 1969; 74:494.</a></li><li><a class="nounderline abstract_t">Aycan Z, Baş VN, Cetinkaya S, et al. Thiamine-responsive megaloblastic anemia syndrome with atrial standstill: a case report. J Pediatr Hematol Oncol 2011; 33:144.</a></li><li><a class="nounderline abstract_t">Srikrupa NN, Meenakshi S, Arokiasamy T, et al. Leber's congenital amaurosis as the retinal degenerative phenotype in thiamine responsive megaloblastic anemia: a case report. Ophthalmic Genet 2014; 35:119.</a></li><li><a class="nounderline abstract_t">Hesdorffer CS, Longo DL. Drug-Induced Megaloblastic Anemia. N Engl J Med 2015; 373:1649.</a></li><li><a class="nounderline abstract_t">Karvellas CJ, Sawyer M, Hamilton M, Mackey JR. Effect of capecitabine on mean corpuscular volume in patients with metastatic breast cancer. Am J Clin Oncol 2004; 27:364.</a></li><li><a class="nounderline abstract_t">Snower DP, Weil SC. Changing etiology of macrocytosis. Zidovudine as a frequent causative factor. Am J Clin Pathol 1993; 99:57.</a></li><li><a class="nounderline abstract_t">Burns ER, Reed LJ, Wenz B. Volumetric erythrocyte macrocytosis induced by hydroxyurea. Am J Clin Pathol 1986; 85:337.</a></li><li><a class="nounderline abstract_t">Engström KG, Löfvenberg E. Treatment of myeloproliferative disorders with hydroxyurea: effects on red blood cell geometry and deformability. Blood 1998; 91:3986.</a></li><li><a class="nounderline abstract_t">Gillessen S, Graf L, Korte W, Cerny T. Macrocytosis and cobalamin deficiency in patients treated with sunitinib. N Engl J Med 2007; 356:2330.</a></li><li><a class="nounderline abstract_t">Billemont B, Izzedine H, Rixe O. Macrocytosis due to treatment with sunitinib. N Engl J Med 2007; 357:1351.</a></li><li><a class="nounderline abstract_t">Rini BI, Choueiri TK, Elson P, et al. Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma. Cancer 2008; 113:1309.</a></li><li><a class="nounderline abstract_t">Schallier D, Trullemans F, Fontaine C, et al. Tyrosine kinase inhibitor-induced macrocytosis. Anticancer Res 2009; 29:5225.</a></li><li><a class="nounderline abstract_t">Rajaraman S, Davis WS, Mahakali-Zama A, et al. An allelic series of mutations in the Kit ligand gene of mice. II. Effects of ethylnitrosourea-induced Kitl point mutations on survival and peripheral blood cells of Kitl(Steel) mice. Genetics 2002; 162:341.</a></li><li><a class="nounderline abstract_t">Aslinia F, Mazza JJ, Yale SH. Megaloblastic anemia and other causes of macrocytosis. Clin Med Res 2006; 4:236.</a></li><li><a class="nounderline abstract_t">Kaferle J, Strzoda CE. Evaluation of macrocytosis. Am Fam Physician 2009; 79:203.</a></li><li><a class="nounderline abstract_t">Seppä K, Sillanaukee P, Saarni M. Blood count and hematologic morphology in nonanemic macrocytosis: differences between alcohol abuse and pernicious anemia. Alcohol 1993; 10:343.</a></li><li><a class="nounderline abstract_t">Savage D, Lindenbaum J. Anemia in alcoholics. Medicine (Baltimore) 1986; 65:322.</a></li><li><a class="nounderline abstract_t">Girard DE, Kumar KL, McAfee JH. Hematologic effects of acute and chronic alcohol abuse. Hematol Oncol Clin North Am 1987; 1:321.</a></li><li><a class="nounderline abstract_t">Balcells A, Ingelmo M, Vivancos J, et al. [Macrocytosis in chronic alcoholism (author's transl)]. Med Clin (Barc) 1979; 73:312.</a></li><li><a class="nounderline abstract_t">Wymer A, Becker DM. Recognition and evaluation of red blood cell macrocytosis in the primary care setting. J Gen Intern Med 1990; 5:192.</a></li><li><a class="nounderline abstract_t">Seppä K, Laippala P, Saarni M. Macrocytosis as a consequence of alcohol abuse among patients in general practice. Alcohol Clin Exp Res 1991; 15:871.</a></li><li><a class="nounderline abstract_t">Latvala J, Parkkila S, Melkko J, Niemelä O. Acetaldehyde adducts in blood and bone marrow of patients with ethanol-induced erythrocyte abnormalities. Mol Med 2001; 7:401.</a></li><li><a class="nounderline abstract_t">Wickramasinghe SN, Malik F. Acetaldehyde causes a prolongation of the doubling time and an increase in the modal volume of cells in culture. Alcohol Clin Exp Res 1986; 10:350.</a></li><li><a class="nounderline abstract_t">Hashimoto Y, Nakayama T, Futamura A, et al. Erythrocyte mean cell volume and genetic polymorphism of aldehyde dehydrogenase 2 in alcohol drinkers. Blood 2002; 99:3487.</a></li><li><a class="nounderline abstract_t">Carvalho NF, Kenney RD, Carrington PH, Hall DE. Severe nutritional deficiencies in toddlers resulting from health food milk alternatives. Pediatrics 2001; 107:E46.</a></li><li><a class="nounderline abstract_t">Hinchliffe RF, Bellamy GJ, Lilleyman JS. Use of the Technicon H1 hypochromia flag in detecting spurious macrocytosis induced by excessive K2-EDTA concentration. Clin Lab Haematol 1992; 14:268.</a></li><li><a class="nounderline abstract_t">Holt JT, DeWandler MJ, Arvan DA. Spurious elevation of the electronically determined mean corpuscular volume and hematocrit caused by hyperglycemia. Am J Clin Pathol 1982; 77:561.</a></li><li><a class="nounderline abstract_t">van Duijnhoven HL, Treskes M. Marked interference of hyperglycemia in measurements of mean (red) cell volume by Technicon H analyzers. Clin Chem 1996; 42:76.</a></li><li><a class="nounderline abstract_t">Weiss GB, Bessman JD. Spurious automated red cell values in warm autoimmune hemolytic anemia. Am J Hematol 1984; 17:433.</a></li><li><a class="nounderline abstract_t">Bessman JD, Banks D. Spurious macrocytosis, a common clue to erythrocyte cold agglutinins. Am J Clin Pathol 1980; 74:797.</a></li><li><a class="nounderline abstract_t">Goossens W, Van Duppen V, Verwilghen RL. K2- or K3-EDTA: the anticoagulant of choice in routine haematology? Clin Lab Haematol 1991; 13:291.</a></li><li><a class="nounderline abstract_t">Rauw J, Wells RA, Chesney A, et al. Validation of a scoring system to establish the probability of myelodysplastic syndrome in patients with unexplained cytopenias or macrocytosis. Leuk Res 2011; 35:1335.</a></li><li><a class="nounderline abstract_t">Inelmen EM, D'Alessio M, Gatto MR, et al. Descriptive analysis of the prevalence of anemia in a randomly selected sample of elderly people living at home: some results of an Italian multicentric study. Aging (Milano) 1994; 6:81.</a></li><li><a class="nounderline abstract_t">den Elzen WP, Westendorp RG, Frölich M, et al. Vitamin B12 and folate and the risk of anemia in old age: the Leiden 85-Plus Study. Arch Intern Med 2008; 168:2238.</a></li><li><a class="nounderline abstract_t">Lam AP, Gundabolu K, Sridharan A, et al. Multiplicative interaction between mean corpuscular volume and red cell distribution width in predicting mortality of elderly patients with and without anemia. Am J Hematol 2013; 88:E245.</a></li><li><a class="nounderline abstract_t">Christensen RD, Jopling J, Henry E, Wiedmeier SE. The erythrocyte indices of neonates, defined using data from over 12,000 patients in a multihospital health care system. J Perinatol 2008; 28:24.</a></li><li><a class="nounderline abstract_t">Dallman PR, Siimes MA. Percentile curves for hemoglobin and red cell volume in infancy and childhood. J Pediatr 1979; 94:26.</a></li><li><a class="nounderline abstract_t">Pappo AS, Fields BW, Buchanan GR. Etiology of red blood cell macrocytosis during childhood: impact of new diseases and therapies. Pediatrics 1992; 89:1063.</a></li><li><a class="nounderline abstract_t">Davenport J. Macrocytic anemia. Am Fam Physician 1996; 53:155.</a></li><li><a class="nounderline abstract_t">Anttila P, Ihalainen J, Salo A, et al. Idiopathic macrocytic anaemia in the aged: molecular and cytogenetic findings. Br J Haematol 1995; 90:797.</a></li><li><a class="nounderline abstract_t">Planche V, Georgin-Lavialle S, Avillach P, et al. Etiologies and diagnostic work-up of extreme macrocytosis defined by an erythrocyte mean corpuscular volume over 130°fL: A study of 109 patients. Am J Hematol 2014; 89:665.</a></li></ol></div><div id="topicVersionRevision">Topic 7166 Version 40.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1257398" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The haematology of hypothyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9040391" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : ABC of clinical haematology. Macrocytic anaemias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1578958" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : A practical approach to the differential diagnosis and evaluation of the adult patient with macrocytic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7833482" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Simultaneous measurement of reticulocyte and red blood cell indices in healthy subjects and patients with microcytic and macrocytic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1280483" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Reticulocyte maturation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4226445" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Folic acid deficiency in patients with skin disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19619756" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Thiamine-responsive megaloblastic anemia syndrome: long term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/671156" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Thiamine-responsive megaloblastic anemia, sensorineural deafness, and diabetes mellitus: A new syndrome?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5767338" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Thiamine-responsive megaloblastic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21285901" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Thiamine-responsive megaloblastic anemia syndrome with atrial standstill: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23638917" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Leber's congenital amaurosis as the retinal degenerative phenotype in thiamine responsive megaloblastic anemia: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26488695" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Drug-Induced Megaloblastic Anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15289729" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Effect of capecitabine on mean corpuscular volume in patients with metastatic breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8422018" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Changing etiology of macrocytosis. Zidovudine as a frequent causative factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3790210" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Volumetric erythrocyte macrocytosis induced by hydroxyurea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9573039" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Treatment of myeloproliferative disorders with hydroxyurea: effects on red blood cell geometry and deformability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17538098" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Macrocytosis and cobalamin deficiency in patients treated with sunitinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17898111" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Macrocytosis due to treatment with sunitinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18618496" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20044640" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Tyrosine kinase inhibitor-induced macrocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12242245" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : An allelic series of mutations in the Kit ligand gene of mice. II. Effects of ethylnitrosourea-induced Kitl point mutations on survival and peripheral blood cells of Kitl(Steel) mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16988104" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Megaloblastic anemia and other causes of macrocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19202968" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Evaluation of macrocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8216878" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Blood count and hematologic morphology in nonanemic macrocytosis: differences between alcohol abuse and pernicious anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3747828" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Anemia in alcoholics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3308825" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Hematologic effects of acute and chronic alcohol abuse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/522526" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : [Macrocytosis in chronic alcoholism (author's transl)].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2341917" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Recognition and evaluation of red blood cell macrocytosis in the primary care setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1755522" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Macrocytosis as a consequence of alcohol abuse among patients in general practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11474133" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Acetaldehyde adducts in blood and bone marrow of patients with ethanol-induced erythrocyte abnormalities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3526962" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Acetaldehyde causes a prolongation of the doubling time and an increase in the modal volume of cells in culture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12001910" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Erythrocyte mean cell volume and genetic polymorphism of aldehyde dehydrogenase 2 in alcohol drinkers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11335767" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Severe nutritional deficiencies in toddlers resulting from health food milk alternatives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1451410" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Use of the Technicon H1 hypochromia flag in detecting spurious macrocytosis induced by excessive K2-EDTA concentration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7081150" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Spurious elevation of the electronically determined mean corpuscular volume and hematocrit caused by hyperglycemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8565238" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Marked interference of hyperglycemia in measurements of mean (red) cell volume by Technicon H analyzers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6496462" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Spurious automated red cell values in warm autoimmune hemolytic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7446489" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Spurious macrocytosis, a common clue to erythrocyte cold agglutinins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1794231" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : K2- or K3-EDTA: the anticoagulant of choice in routine haematology?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21704372" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Validation of a scoring system to establish the probability of myelodysplastic syndrome in patients with unexplained cytopenias or macrocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7918735" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Descriptive analysis of the prevalence of anemia in a randomly selected sample of elderly people living at home: some results of an Italian multicentric study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19001201" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Vitamin B12 and folate and the risk of anemia in old age: the Leiden 85-Plus Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23828763" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Multiplicative interaction between mean corpuscular volume and red cell distribution width in predicting mortality of elderly patients with and without anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17972890" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The erythrocyte indices of neonates, defined using data from over 12,000 patients in a multihospital health care system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/758417" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Percentile curves for hemoglobin and red cell volume in infancy and childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1534402" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Etiology of red blood cell macrocytosis during childhood: impact of new diseases and therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8546042" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Macrocytic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7669657" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Idiopathic macrocytic anaemia in the aged: molecular and cytogenetic findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24668797" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Etiologies and diagnostic work-up of extreme macrocytosis defined by an erythrocyte mean corpuscular volume over 130°fL: A study of 109 patients.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
